The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia.

@article{Frei1965TheEO,
  title={The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia.},
  author={E. Frei and M. Karon and R. H. Levin and E. Freireich and R. Taylor and J. Hananian and O. Selawry and J. Holland and B. Hoogstraten and I. Wolman and E. Abir and A. Sawitsky and S. Lee and S. Mills and E. Burgert and C. Spurr and R. Patterson and F. Ebaugh and G. James and J. H. Moon},
  journal={Blood},
  year={1965},
  volume={26 5},
  pages={
          642-56
        }
}
1. Combinations of effective agents produce at least an additive increase in complete remission rates over that which can be achieved when the agents are used individually. 2. Patients who do not achieve complete remission with initial treatment have a significantly shorter survival. 3. Alternating MTX and 6-MP at 28-day intervals during remission does not prolong the duration of remission over that of combined concurrent 6-MP and MTX. 4. The administration of folic acid antagonists… Expand
Additive therapy in the maintenance of remission in acute lymphoblastic leukemia of childhood: The effect of the initial leukocyte count
TLDR
Results indicate that additive therapy is beneficial in those patients with the most favorable prognosis and that the prognostic effects of the initial WBC must be given careful consideration in future protocol design, patient randomization, and data analysis of controlled clinical trials. Expand
Clinical study of daunomycin and prednisone for induction of remission in children with advanced leukemia.
TLDR
Daunomycin and prednisone are a highly effective drug combination for induction of remissions in children with leukemia refractory to conventional antileukemic drugs. Expand
Induction and maintenance of remission in acute leukemia
TLDR
There was no statistically significant difference between the two maintenance regimens of vincristine, daunorubicin, and prednisone for induction followed by consolidation courses every 6 months with these drugs and either 6‐mercaptopurine and methotrexate (plan A) or metotrexate alone (plan B) for maintenance of remission. Expand
A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia
TLDR
6MP given on the present continuous intravenous infusion schedule overcomes the limited and variable bioavailability of oral 6MP but shows limited activity as induction agent in children with recurrent ALL. Expand
Interrupted vs. continued maintenance therapy in childhood acute leukemia
TLDR
Results indicate a significant advantage for continuing maintenance therapy at 2 and 6 months after the start of complete bone marrow remission. Expand
Dexamethasone vs . prednisone in pediatric acute lymphoblastic leukemia
TLDR
Both prednisone (PDN) and dexamethasone (DXM) are glucocorticoids used in induction therapy, with different anti-leukemic efficacy, central nervous system (CNS) penetration, and toxicity profiles. Expand
Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia: Clinical Facts and Fiction
TLDR
Investigation of the antileukemic mechanisms of 6-mercaptopurine and methotrexate maintenance therapy finds that maintenance therapy is as important as the more intensive and toxic earlier treatment phases, and often more challenging. Expand
Clinical investigations in the treatment of meningeal leukemia: radiation therapy regimens vs. conventional intrathecal methotrexate.
TLDR
None of the radiation regimens was superior to IT MTX when the following parameters were considered: duration of CNS remission; duration of existing bone marrow remission; survival from onset of meningeal leukemia; and number of CNS relapses. Expand
The effect of the sequence of administration of cytoxan and methotrexate on the life-span of L1210 leukemic mice.
TLDR
Early administration of a high priming dose of Cyt or MTX apparently lowers the tumor cell population so that scheduled doses of MTX can kill tumor cells more effectively. Expand
Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy
TLDR
Outcome within risk groups was not significantly affected by the speed of rotation of drug pairs during continuation treatment, and various high-risk subgroups had apparently improved responses to this treatment. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
The Effect of 6-Mercaptopurine on the Duration of Steroid-induced Remissions in Acute Leukemia: A Model for Evaluation of Other Potentially Useful Therapy
TLDR
The study was stopped after analysis of the remission times of 21 pairs of patients, since patients maintained on placebo were treated with 6-MP when relapse occurred, and overall survival was not significantly different for the two treatment programs. Expand
Studies of Sequential and Combination Antimetabolite Therapy in Acute Leukemia: 6-Mercaptopurine and Methotrexate
TLDR
It may be concluded therefore that new agents can be effectively studied in patients with "late" disease and responsiveness to drug therapy is maintained as the disease progresses temporally. Expand
Acute childhood leukemia: a ten-year study.
TLDR
A comparison of long-term survivors with less favorably responding patients should be of interest, and several recent articles1-4 deal with the therapeutic results achieved with the newer agents. Expand
The comparison of 6-mercaptopurine with the combination of 6-mercaptopurine and azaserine in the treatment of acute leukemia in children: results of a cooperative study.
TLDR
In 125 cases of previously untreated acute leukemia in children, no significant difference was seen in the percentage of complete remissions obtained when 6-mercaptopurine was used alone or when 6 -mercaptoburine and azaserine were used in combination. Expand
Intrathecal aminopterin therapy of meningeal leukemia.
TLDR
Intrathecal methotrexate (Amethopterin) has been used for the treatment of meningeal leukemia and at dosages usually employed, this therapy has often been adequate to control symptoms, but in cases which do not respond, further increments in dosage have been limited by concern regarding neurotoxicity. Expand
The effect of chemotherapy on acute leukemia in the human.
TLDR
The risk of death during periods of active disease has not changed during the past 10 years and the improved survival can be attributed directly to the duration of the hematologic responses resulting from chemotherapy. Expand
Intrathecal amethopterin in neurological manifestations of leukemia.
TLDR
The difficulty in managing acute leukemia in children is enhanced by the occurrence of neurological manifestations, and current chemotherapeutic agents are only partially effective against the leukemic cell in the central nervous system in the conventional dosage and route of administration. Expand
RESPONSE OF ACUTE LYMPHOCYTIC LEUKEMIAS TO THE PURINE ANTAGONIST 6‐MERCAPTOPURINE
TLDR
Experimental findings strongly indicate that the variant lines produced by the use of these antimetabolites arise by mutation, and two resistant sublines of leukemia L1210 have been developed using 6-mercaptopurine as the selective agent. Expand
Various Combinations of Isoniazid with Streptomycin or with P.A.S. in the Treatment of Pulmonary Tuberculosis
  • Medicine
  • British medical journal
  • 1955
TLDR
It was concluded that the combination P.A.S.S., in combination with isoniazid, on a total of 391 patients after three months' treatment was of the same order of effectiveness as streptomycin 1 g. Expand
LYMPHOGENOUS (LYMPHATIC) LEUKEMIA: DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC CONSIDERATIONS BASED ON AN ANALYSIS OF ITS MORPHOLOGIC AND CLINICAL VARIANTS
TLDR
Until the possible relations of leukemia to neoplastic, metabolic and infectious diseases have received greater elucidation no classification of the types of lymphogenous leukemia can be wholly satisfactory. Expand
...
1
2
3
4
...